TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines. It develops medicines that helps restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. The company's product pipeline focuses on augmenting tissue Tregs to address critical treatment gaps and offers TRB-061, a phase 1 trial TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRB-061 is in clinical development for moderate-to-severe atopic dermatitis (AD). It is also developing TRB-071, an investigational CD30 agonist designed to both augment tissue Tregs and block an immune system inflammatory pathway. The company was incorporated in 2018 and is based in South San Francisco, California. Address: 269 East Grand Avenue, South San Francisco, CA, United States, 94080